Will This Climbing Cardiac Stock Flourish or Flatline?

Before you go, we thought you'd like these...
Before you go close icon

Looking for health care's biggest gainers on the season? Boston Scientific  is a name you should know. This device stock has surged by more than 95% in 2013, blowing away investors who have been troubled by the company's slumping sales and lagging cardiac rhythm management business in recent quarters. Boston Scientific showed progress in its second quarter earnings, but is this stock's momentum about to fall flat?

Boston Scientific posted flat sales in its third-quarter earnings release on Thursday, but that didn't stop investors from hammering this stock to the tune of a 6% decline. While the company's finances didn't disappoint on any major basis, the company's latest restructuring plan -- a deal that will see another 1,000 to 1,500 jobs cut as Boston Scientific looks to control costs -- has investors worried that this company's comeback could fall short.

Is Boston Scientific headed for a stock disaster, or will it keep up its momentum that has pleased Wall Street this year? Find out in the video below, where Fool contributor Dan Carroll tells you what you need to know about Boston Scientific's latest restructuring plan and how this cardiac device king can keep up with its top rivals in this hotly contested industry.

The growth stock that's poised to blow away Wall Street
Boston Scientific's been a growth investor's dream in 2013, but you don't have to look far for what could be the greatest growth gift on the market. One incredible tech stock is growing twice as fast as Google and Facebook, and more than three times as fast as Amazon.com and Apple. Watch our jaw-dropping investor alert video today to find out why The Motley Fool's chief technology officer is putting $117,238 of his own money on the table, and why he's so confident this will be a huge winner in the rest of 2013 and beyond. Just click here to watch!

The article Will This Climbing Cardiac Stock Flourish or Flatline? originally appeared on Fool.com.

Fool contributor Dan Carroll has no position in any stocks mentioned. The Motley Fool owns shares of Medtronic. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story

Sign up for Finance Report by AOL and get everything from business news to personal finance tips delivered directly to your inbox daily!

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.

People are Reading